Revelation Biosciences, Inc. reported a net loss of $3,315,513 for the three months ended September 30, 2026, compared with $1,907,176 for the same period in 2025. Net cash used for operating activities was $2.6 million versus $1.6 million. For the nine months ended September 30, 2026, net loss was $9,647,948, compared with $6,402,643 for the same period in 2025.
Cash and cash equivalents were $9,121,630 as of September 30, 2026, compared with $10,700,331 as of December 31, 2025. Based on current operating plans and projections, Revelation believes its cash and cash equivalents are sufficient to fund operations into the second quarter of 2027.
The company selected a full-service contract research organization with global operations for its upcoming study of Gemini in patients with acute kidney injury. An independent market assessment indicated a potential $94 billion total addressable market for Gemini. Revelation describes Gemini as its proprietary formulation of PHAD, a TLR4 agonist; it is evaluating Gemini for acute kidney injury and developing it for chronic kidney disease, severe-burn hyperinflammation and infection, and prevention of post-surgical infection.
Revelation Biosciences, Inc. (REVB), a clinical-stage developer of GEM-AKI and GEM-CKD, reported a nine-month net loss of $9,647,948, versus $6,402,643 for the nine months ended September 30, 2025. Operating expenses were $10,138,317, including $4,808,183 in research and development; $2,247,519 was for GEM-AKI.
Cash and cash equivalents were $9,121,630 as of September 30, 2026. Operating activities used $8,133,206 during the nine months; financing activities provided $6,666,012, primarily from the January Class I warrant inducement. The company has never generated revenue and says its cash is not expected to sustain operations within one year after the September 30, 2026 statements were issued, which raises substantial doubt about its ability to continue as a going concern. It plans to seek additional equity or debt financing.
Revelation says its current listed-securities market value is below $5 million. Nasdaq's rule requires automatic delisting if it remains below that threshold for 30 consecutive business days, and becomes operative upon termination of the SEC stay. On October 20, 2026, the company effected a 1-for-7 reverse split, adjusting specified warrant exercise prices from $12.46 to $3.29 and Class G underlying shares from 489,250 to 1,852,908.
Revelation Biosciences, Inc. (REVB) disclosed that its Compensation Committee approved new Restricted Stock Awards for senior executives under the Amended and Restated 2021 Equity Incentive Plan, effective August 17, 2026. Chief Executive Officer James Rolke received 208,076 restricted shares and Chief Financial Officer Chester S. Zygmont, III received 208,073 restricted shares.
The awards vest in four equal 25% tranches based on the earlier of market capitalization milestones of $30 million, $60 million, $90 million, and $120 million sustained for twenty consecutive trading days, or time-based anniversaries at two and four years from grant. The awards fully vest immediately before a Change in Control, or upon certain terminations (death, termination without Cause, or resignation for Good Reason), and are otherwise forfeited if service ends under other circumstances. The form of Restricted Stock Award Agreement is filed as an exhibit.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
REVELATION BIOSCIENCES, INC. (REVB) reported that director Lakhmir S. Chawla acquired 32,011 shares of common stock on August 17, 2026 via a restricted stock award granted at $0.00 per share under the company’s 2021 Equity Incentive Plan. Following this grant, Chawla holds 44,169 shares directly. The award vests 50% on the two-year anniversary and 50% on the four-year anniversary of the grant date, subject to continued service, with potential acceleration upon certain performance milestones.
REVELATION BIOSCIENCES, INC. (REVB) reported that its Chief Financial Officer, Chester S. Zygmont III, received a restricted stock award of 208,073 shares of Common Stock under the company’s 2021 Equity Incentive Plan. The award vests with 50% on the two-year anniversary of the grant date and the remaining 50% on the four-year anniversary, subject to continued service and possible acceleration upon performance milestones. On the same date, Zygmont made a bona fide gift of 208,073 shares to The Zygmont Family Trust, which now holds 300,136 shares indirectly, and an affiliated LLC holds an additional 2 shares indirectly.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of Revelation Biosciences, Inc. common stock. They collectively report 209,212 shares of common stock, representing 4.99% of the class, held through Armistice Capital Master Fund Ltd.
Armistice Capital, as investment manager to the Master Fund, has shared power to vote and dispose of all 209,212 shares and no sole voting or dispositive power. Steven Boyd, as managing member of Armistice Capital, may be deemed to share this beneficial ownership. The Master Fund retains the right to receive dividends and sale proceeds from these securities, while specifically disclaiming beneficial ownership because voting and dispositive authority reside with Armistice Capital.
Revelation Biosciences, Inc. reported financial results for the three and six months ended June 30, 2026 and highlighted progress on its Gemini programs. Net loss was $3,323,384, or $(0.87) per share, for the quarter and $6,332,435, or $(3.41) per share, for the six-month period.
Cash and cash equivalents were $11,482,792 as of June 30, 2026, compared with $10,700,331 at December 31, 2025, and the company expects this to fund operations through the first quarter of 2027. Total stockholders’ equity was $10,066,986, with 3,908,420 common shares outstanding. Operationally, Revelation advanced start-up activities for a Phase 2/3 acute kidney injury study of Gemini, formed and expanded an Acute Kidney Injury Advisory Board, and cited an independent assessment indicating a potential $94 billion total addressable market for Gemini.